Rheumatoid ArthritisPhase 2NCT00928512
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A Phase 2 study testing Secukinmab in people with Rheumatoid Arthritis, run by Novartis Pharmaceuticals at 58 sites in 11 countries.
Trial summary
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- Secukinmab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 237 participants
- Where
- 58 sitesin 11 countries
- Study dates
- Jul 2009to Mar 2011
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Presence of RA classified by ACR 1987 revised criteria. Patients with active RA should have been on MTX for at least 3 months and must currently be treated with a stable dose of MTX (> or =7.5 mg/week - < or = 25 mg/week) for at least 4 weeks
- At Baseline: Disease activity criteria defined by > or = 6 out of 28 tender joints and > or = 6 out of 28 swollen joints WITH either Screening value of hsCRP > or = 10 mg/L OR ESR > or = 28 mm/1st hr
Who cannot join
- RA patients functional status class IV classified according to the ACR 1991 revised criteria
- Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine)
- Any therapy by intra-articular injections (e.g. corticosteroid) required for treatment of acute RA flare within 4 weeks before randomization
- Other protocol-defined inclusion/exclusion criteria may apply
Trial locations and contacts
58 sites in 11 countries.
58 sites in 11 countries
United States13 sites
Novartis Investigative Site
Coeur d'Alene, Idaho, 83814
Novartis Investigative Site
Greenville, South Carolina, 29601
Novartis Investigative Site
Jackson, Tennessee, 38305
Novartis Investigative Site
Kalamazoo, Michigan, 49048
Novartis Investigative Site
Lincoln, Nebraska, 68516
Novartis Investigative Site
Little Rock, Arkansas, 72205
Novartis Investigative Site
Mesa, Arizona, 85202
Novartis Investigative Site
Oklahoma City, Oklahoma, 73103
Novartis Investigative Site
Peoria, Arizona, 85381
Novartis Investigative Site
Rochester, New York, 14609
Novartis Investigative Site
Santa Monica, California, 90404
Novartis Investigative Site
Springfield, Illinois, 62704
Novartis Investigative Site
Tulsa, Oklahoma, 74135-2920
Russia9 sites
Novartis Investigative Site
Moscow, 115522
Novartis Investigative Site
Moscow, 117049
Novartis Investigative Site
Moscow, 129327
Novartis Investigative Site
Saint Petersburg, 190068
Novartis Investigative Site
Saint Petersburg, 194104
Novartis Investigative Site
Saint Petersburg, 195257
Novartis Investigative Site
Tula, 300053
Novartis Investigative Site
Tver', 170036
Novartis Investigative Site
Yaroslavl, 150003
Germany6 sites
Novartis Investigative Site
Bayreuth, 95445
Novartis Investigative Site
Berlin, 14059
Novartis Investigative Site
Hamburg, 22081
Novartis Investigative Site
Hamburg, 22415
Novartis Investigative Site
Hildesheim, 31134
Novartis Investigative Site
München, 80639
Japan6 sites
Novartis Investigative Site
Iizuka, Fukuoka, 820-8505
Novartis Investigative Site
Kawagoe, Saitama, 350-1103
Novartis Investigative Site
Kobe, Hyōgo, 650-0044
Novartis Investigative Site
Kobe, Hyōgo, 658-0011
Novartis Investigative Site
Kurashiki, Okayama-ken, 710-8522
Novartis Investigative Site
Sagamihara, Kanagawa, 228-8522
Taiwan6 sites
Novartis Investigative Site
Changhua, 500
Novartis Investigative Site
Kaohsiung City, 81346
Novartis Investigative Site
Niaosong Township, Taiwan, 83301
Novartis Investigative Site
Taichung, Taiwan, 40447
Novartis Investigative Site
Taichung, Taiwan, 40705
Novartis Investigative Site
Taichung, Taiwan ROC, 40201
Czechia4 sites
Novartis Investigative Site
Ostrava, Czech Republic, 72200
Novartis Investigative Site
Pardubice, Czech Republic, 53002
Novartis Investigative Site
Prague, 128 50
Novartis Investigative Site
Uherské Hradiště, Czech Republic, 686 01
South Korea4 sites
Novartis Investigative Site
Anyang-si, Gyeonggi-do, 431-070
Novartis Investigative Site
Busan, Busan, 602-739
Novartis Investigative Site
Seoul, Korea, 137-701
Novartis Investigative Site
Seoul, 143-729
Hungary3 sites
Novartis Investigative Site
Budapest, 1062
Novartis Investigative Site
Debrecen, 4032
Novartis Investigative Site
Gyula, 5700
Poland3 sites
Novartis Investigative Site
Bialystok, 15-337
Novartis Investigative Site
Bialystok, 15-461
Novartis Investigative Site
Lublin, 20-607
Slovakia3 sites
Novartis Investigative Site
Banská Bystrica, 975 17
Novartis Investigative Site
Košice, Slovak Republic, 040 15
Novartis Investigative Site
Piešťany, Slovak Republic, 921 12
About this study
Official title: A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.
- Conditions
- Rheumatoid Arthritis
- Being tested
- Secukinmab, Placebo
- Keywords
- Rheumatoid Arthritis, RA, ACR, inflammatory joints
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SecukinmabDrug
Also called AIN457
Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
PlaceboDrug
Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
| Study group | Role | What they receive |
|---|---|---|
| Secukinumab 25mg | Experimental | Secukinumab 25mg s.c. q4wk Receives: Drug: Secukinmab |
| Secukinumab 75mg | Experimental | Secukinumab 75mg s.c. q4wk Receives: Drug: Secukinmab |
| Secukinumab 150mg | Experimental | Secukinumab 150mg s. c. q4wk Receives: Drug: Secukinmab |
| Secukinumab 300mg | Experimental | Secukinumab 300mg s.c. q4wk Receives: Drug: Secukinmab |
| Secukinumab Placebo | Placebo comparator | Secukinumab Placebo s.c. q4wk Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks
A participant was considered to have achieved the incidence of response (ACR20 criteria) if he/she had at least a 20% improvement in both the tender and swollen 28-joint counts and had at least 20% improvement in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assesseddisability (Health Assessment Questionnaire [HAQ©] score)and acute phase rectant (C-reactive protein [hsCRP]/ESR).
Measured: 16cweeks
Secondary outcomes (17)
Number of Participants Who Achieved an ACR50 or ACR70 Response at Week 16
A participant was considered as improved according to the ACR50 or ACR70 criteria if he/she had at least a 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient self-assessed disability (Health Assessment Questionnaire [HAQ©] score) and Acute phase reactant (C-reactive protein [hsCRP]/ESR). Participants were defined as ACR50/70 responders at a given post-randomization visit if they satisfied the ACR50/70 criteria, respectively. Participants were considered ACR50/70 nonresponders if they failed the ACR50/70 criteria respectively. Participants who prematurely discontinued from study due to insufficient therapeutic effect were also considered nonresponders.
Measured: Week 16
Number of Participants Who Achieved an ACR20, ACR50 or ACR70 Response up to Week 16
A participant was considered as improved according to the ACR20, ACR50 or ACR70 criteria if he/she had as least a 20%, 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assessed disability and acute phase rectant or Erythrocyte sedimentation rate (ESR).
Measured: at Weeks2, 4, 8, 12, 16
Change From Baseline in Disease Activity Score 28 Using CRP (DAS28-CRP)
The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient's 'global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission. The DAS28-CRP was derived from swollen joint count, tender joint count, hsCRP and patient's global assessment of disease activity.
Measured: Baseline, week 16
Change From Baseline in Medical Outcome Short Form (36) Health Survey (SF-36® v2)
The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health) which can be aggregated to derive a physical-component summary score and a mental-component score. Scores are normally determined with the use of norm-based methods which standardize scores based on an assessment of the general U.S. population free of chronic conditions. The scores range for each subscale from 0 to 10, and the composite score ranges from 0 to 100, with the higher scores indicative of better health.
Measured: Baseline, week 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 16
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much) based on their experience of fatigue during the past 2 weeThe scale score was computed by summing the item scores, after reversing those items that were worded in the negative direction. When there were missing item scores, the subscale score was computed by summing the non-missing item scores, multiplying by 13 (the total number of items in the scale) and dividing by the number of non-missing items. The latter rule applied only when at least half of the items (seven or more) were non-missing. FACIT-Fatigue subscale scores range from 0 to 52, where higher scores represent less fatigue.
Measured: Baseline, Week 16
Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 16
The distribution of EULAR response criteria was according to DAS28-CRP at Week 16. EULAR response criteria are based on DAS28-CRP status in combination with DAS28-CRP improvements. The EULAR response criteria are as follows: Week 16 DAS28-CRP <3.2 with DAS28-CRP improvement >1.2 corresponds to 'good response'; Week 16 DAS28-CRP <3.2 with DAS28-CRP improvement between 0.6 to 1.2, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement >1.2 or from 0.6 to 1.2, or WeeK 16 DAS28-CRP >5.1 with DAS28-CRP improvement >1.2 correspond to 'moderate response; Week 16 DAS28-CRP <3.2 with DAS28-CRP improvement <0.6, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement <0.6, or Week 16 DAS28-CRP >5.1 with DAS28-CRP improvement between 0.6 to 1.2 or <0.6 correspond to 'no response'.
Measured: Week 16
Change From Baseline in Rheumatoid Factor (RF) Concentrations at Week 16
Only values that were above normal range (12 U/mL) were were included.
Measured: Baseline, Week 16
Anti-CCP (Cyclic Citrulinated Peptide) Antibodies Concentrations at Baseline and at Week 16
Only values that were above normal range (20 units) were included.
Measured: Baseline, Week 16
Change From Baseline in ACR Component: Adjusted Swollen 28-joint Count at Week 16
Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive result for swollen joint count. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. Whenever possible, the same evaluator performed these assessments at all visits. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., S) was less than 28, the number of swollen joints (e.g., s) was scaled up proportionately (i.e., 28*(s/S)).
Measured: Baseline, week 16
Change From Baseline in Disease Activity Score 28 Using ESR (DAS28-ESR) at Week 16
The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient's 'global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission.The DAS28 was also derived using erythrocyte sedimentation rate (ESR) (referred to as DAS28-ESR).
Measured: Baseline, week 16
Change From Baseline in ACR Component: Adjusted Tender 28-joint Count at Week 16
The ACR tender joint count (28 joints) was done by scoring several different aspects of tenderness as assessed by pressure and joint manipulation on physical examination. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., T) was less than 28, the number of tender joints (e.g., t) was scaled up proportionately (i.e., 28*(t/T)).
Measured: Baseline, week 16
Change From Baseline in ACR Component: Patient's Assessment of RA Pain at Week 16
The patient's assessment of pain was performed at all visits using 100 mm visual analog scale (VAS) ranging from "no pain" to "unbearable pain" after the question "Please indicate with a vertical mark ( | ) through the horizontal line the most pain you had from your rheumatoid arthritis over the last 24 hours.
Measured: Baseline, week 16
Change From Baseline in ACR Component: Patient's Global Assessment of Disease Activity at Week 16
The patient's global assessment of disease activity was performed at the visits on a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, "Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing".
Measured: Baseline, week 16
Change From Baseline in ACR Component: Physician's Global Assessment of Disease Activity at Week 16
The physician's global assessment of disease activity was performed at the visits usingon a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, "Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing".
Measured: Baseline, week 16
Change From Baseline in ACR Component: Health Assessment Questionnaire (HAQ©) Score at Week 16
HAQ© was used to assess physical ability and functional status of patients as well as quality of life at the visits in these 8 categories assessed by the Disability Index: dressing \& grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Patients report amount of difficulty they have in performing 2 or 3 specific activities. There are 4 possible responses (0, 1, 2, 3) for these questions which include types of assistance, if any; the participant uses for his/her usual activities: 0: without any difficulty- No assistance is needed; 1: with some difficulty - A special device is used by the patient in his/her usual activities; 2: with much difficulty - The patient usually needs help from another person. 3: Unable to do - the patient usually needs both a special device and help from another person. Scores of 0 - 1 are generally considered to represent mild to moderate difficulty, 1-2 moderate to severe disability, and 2 -3 severe to very severe disability.
Measured: Baseline, week 16
Change From Baseline in ACR Component: High Sensitivity C-reactive Protein (hsCRP)
Blood for this assessment was obtained at the visits in order to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.Since the results of this test may have unblinded study personnel, results from the central lab were provided for screening and baseline only. The hsCRP results from samples collected during the treatment period were revealed only after final database lock.
Measured: Baseline, week 16
Change From Baseline in ACR Component: Erythrocyte Sedimentation Rate (ESR) at Week 16
Blood for ESR, which is helpful to diagnose inflammatory diseases and to monitor disease activity and response to therapy, was obtained at the visits.
Measured: Baseline, week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2009 (estimated)
- Study startJul 2009
- Primary completionMar 2011
- Study completionMar 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 237 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00928512
- Sponsor's protocol ID
- CAIN457F2201
- Other IDs
- 2009-011000-34, 2009
- Status last verified
- Oct 2015
- First submitted
- 25 Jun 2009
- Last updated
- 30 Oct 2015
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014 Mar;41(3):414-21. doi: 10.3899/jrheum.130637. Epub 2014 Jan 15.
PubMed 24429175Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013 Jun;72(6):863-9. doi: 10.1136/annrheumdis-2012-201601. Epub 2012 Jun 23.
PubMed 22730366
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate
- ClinicalTrials.gov ID
- NCT00928512
- Acronym / sponsor ID
- CAIN457F2201
- Conditions
- Rheumatoid Arthritis
- Keywords
- Rheumatoid Arthritis, RA, ACR, inflammatory joints
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 237 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Jul 2009
- Primary completion
- Mar 2011 (actual)
- Study completion
- Mar 2011 (actual)
- First posted
- 26 Jun 2009 (estimated)
- Results
- Posted 30 Jul 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Secukinumab 25mg | Experimental | Drug: SecukinmabSecukinumab 25mg s.c. q4wk |
| Secukinumab 75mg | Experimental | Drug: SecukinmabSecukinumab 75mg s.c. q4wk |
| Secukinumab 150mg | Experimental | Drug: SecukinmabSecukinumab 150mg s. c. q4wk |
| Secukinumab 300mg | Experimental | Drug: SecukinmabSecukinumab 300mg s.c. q4wk |
| Secukinumab Placebo | Placebo comparator | Drug: PlaceboSecukinumab Placebo s.c. q4wk |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Presence of RA classified by ACR 1987 revised criteria. Patients with active RA should have been on MTX for at least 3 months and must currently be treated with a stable dose of MTX (> or =7.5 mg/week - < or = 25 mg/week) for at least 4 weeks
- At Baseline: Disease activity criteria defined by > or = 6 out of 28 tender joints and > or = 6 out of 28 swollen joints WITH either Screening value of hsCRP > or = 10 mg/L OR ESR > or = 28 mm/1st hr
Key exclusion criteria (4 listed)
- RA patients functional status class IV classified according to the ACR 1991 revised criteria
- Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine)
- Any therapy by intra-articular injections (e.g. corticosteroid) required for treatment of acute RA flare within 4 weeks before randomization
- Other protocol-defined inclusion/exclusion criteria may apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SecukinmabAlso: AIN457Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously. | Drug | Secukinumab 150mg, Secukinumab 25mg, Secukinumab 300mg, Secukinumab 75mg |
| PlaceboSecukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously. | Drug | Secukinumab Placebo |
Primary outcome
Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks
Time frame: 16cweeks
A participant was considered to have achieved the incidence of response (ACR20 criteria) if he/she had at least a 20% improvement in both the tender and swollen 28-joint counts and had at least 20% improvement in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assesseddisability (Health Assessment Questionnaire [HAQ©] score)and acute phase rectant (C-reactive protein [hsCRP]/ESR).
17 secondary outcomes
Number of Participants Who Achieved an ACR50 or ACR70 Response at Week 16
Time frame: Week 16
Number of Participants Who Achieved an ACR20, ACR50 or ACR70 Response up to Week 16
Time frame: at Weeks2, 4, 8, 12, 16
Change From Baseline in Disease Activity Score 28 Using CRP (DAS28-CRP)
Time frame: Baseline, week 16
Change From Baseline in Medical Outcome Short Form (36) Health Survey (SF-36® v2)
Time frame: Baseline, week 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 16
Time frame: Baseline, Week 16
Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 16
Time frame: Week 16
Change From Baseline in Rheumatoid Factor (RF) Concentrations at Week 16
Time frame: Baseline, Week 16
Anti-CCP (Cyclic Citrulinated Peptide) Antibodies Concentrations at Baseline and at Week 16
Time frame: Baseline, Week 16
Change From Baseline in ACR Component: Adjusted Swollen 28-joint Count at Week 16
Time frame: Baseline, week 16
Change From Baseline in Disease Activity Score 28 Using ESR (DAS28-ESR) at Week 16
Time frame: Baseline, week 16
Change From Baseline in ACR Component: Adjusted Tender 28-joint Count at Week 16
Time frame: Baseline, week 16
Change From Baseline in ACR Component: Patient's Assessment of RA Pain at Week 16
Time frame: Baseline, week 16
Change From Baseline in ACR Component: Patient's Global Assessment of Disease Activity at Week 16
Time frame: Baseline, week 16
Change From Baseline in ACR Component: Physician's Global Assessment of Disease Activity at Week 16
Time frame: Baseline, week 16
Change From Baseline in ACR Component: Health Assessment Questionnaire (HAQ©) Score at Week 16
Time frame: Baseline, week 16
Change From Baseline in ACR Component: High Sensitivity C-reactive Protein (hsCRP)
Time frame: Baseline, week 16
Change From Baseline in ACR Component: Erythrocyte Sedimentation Rate (ESR) at Week 16
Time frame: Baseline, week 16
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 24429175Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014 Mar;41(3):414-21. doi: 10.3899/jrheum.130637. Epub 2014 Jan 15.
- Derived from this study: PubMed 22730366Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013 Jun;72(6):863-9. doi: 10.1136/annrheumdis-2012-201601. Epub 2012 Jun 23.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
58 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Secukinmab in people with Rheumatoid Arthritis, run by Novartis Pharmaceuticals at 58 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 58 sites in United States, Russia, Germany, Japan, Taiwan and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 30 Jul 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks (time frame: 16cweeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00928512, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2015.